Literature DB >> 23188179

Scaling up antiretroviral therapy in resource-limited settings: adapting guidance to meet the challenges.

Marco Vitoria1, Stefano Vella, Nathan Ford.   

Abstract

PURPOSE OF REVIEW: This review describes the evolution of WHO guidelines for antiretroviral therapy (ART) in HIV-infected individuals, considering the key epidemiological, scientific, programmatic, and political changes over the last decade, and highlights the major trends for the management of the HIV disease in future guidelines revisions. RECENT
FINDINGS: In the last few years, new evidence has emerged supporting the potential preventive benefit of ART in reducing HIV transmission. This, together with the potential clinical benefits of earlier initiation of therapy, has led to the consideration of the broader strategic use of ART, taking into account the clinical and public health benefit, and programmatic feasibility.
SUMMARY: In 2002, WHO established its first guidelines for ART use, primarily focused on a public health approach for resource-limited settings. These recommendations were updated in 2003, 2006, and 2010, incorporating progressive changes reflecting progressive increase in the knowledge of HIV pathogenesis, development of new drugs and diagnostics, and increased experience of HIV treatment and prevention programs. The impact of several international political commitments and scale-up initiatives such as the 3 by 5 Initiative, Universal Access targets, and the Treatment 2.0 Strategy were also important drivers of the global response, increasing the treatment coverage and catalyzing the necessary environment for the establishment of operational and programmatic components for an expanded and sustainable global response to HIV/AIDS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23188179     DOI: 10.1097/COH.0b013e32835b8123

Source DB:  PubMed          Journal:  Curr Opin HIV AIDS        ISSN: 1746-630X            Impact factor:   4.283


  19 in total

1.  Determination of HIV Status in African Adults With Discordant HIV Rapid Tests.

Authors:  Jessica M Fogel; Estelle Piwowar-Manning; Kelsey Donohue; Vanessa Cummings; Mark A Marzinke; William Clarke; Autumn Breaud; Agnès Fiamma; Deborah Donnell; Michal Kulich; Jessie K K Mbwambo; Linda Richter; Glenda Gray; Michael Sweat; Thomas J Coates; Susan H Eshleman
Journal:  J Acquir Immune Defic Syndr       Date:  2015-08-01       Impact factor: 3.731

Review 2.  Antiretroviral therapy: Shifting sands.

Authors:  V K Sashindran; Rajeev Chauhan
Journal:  Med J Armed Forces India       Date:  2016-01-05

3.  Treatment to Prevent HIV Transmission in Serodiscordant Couples in Henan, China, 2006 to 2012.

Authors:  M Kumi Smith; Daniel Westreich; Huixin Liu; Lin Zhu; Lan Wang; Wensheng He; Jianping Zhou; William C Miller; Myron S Cohen; Ning Wang
Journal:  Clin Infect Dis       Date:  2015-03-13       Impact factor: 9.079

4.  Editorial commentary: immunodeficiency at start of antiretroviral therapy: the persistent problem of late presentation to care.

Authors:  Nathan Ford; Edward J Mills; Matthias Egger
Journal:  Clin Infect Dis       Date:  2014-12-16       Impact factor: 9.079

5.  Discordant Impact of HLA on Viral Replicative Capacity and Disease Progression in Pediatric and Adult HIV Infection.

Authors:  Emily Adland; Paolo Paioni; Christina Thobakgale; Leana Laker; Luisa Mori; Maximilian Muenchhoff; Anna Csala; Margaret Clapson; Jacquie Flynn; Vas Novelli; Jacob Hurst; Vanessa Naidoo; Roger Shapiro; Kuan-Hsiang Gary Huang; John Frater; Andrew Prendergast; Julia G Prado; Thumbi Ndung'u; Bruce D Walker; Mary Carrington; Pieter Jooste; Philip J R Goulder
Journal:  PLoS Pathog       Date:  2015-06-15       Impact factor: 6.823

6.  Quantitative Assessment of Intra-Patient Variation in CD4+ T Cell Counts in Stable, Virologically-Suppressed, HIV-Infected Subjects.

Authors:  Claire L Gordon; Allen C Cheng; Paul U Cameron; Michael Bailey; Suzanne M Crowe; John Mills
Journal:  PLoS One       Date:  2015-06-25       Impact factor: 3.240

7.  Editorial commentary: Comparative efficacy of lamivudine and emtricitabine: comparing the results of randomized trials and cohorts.

Authors:  Nathan Ford; Andrew Hill; Marco Vitoria; Edward J Mills
Journal:  Clin Infect Dis       Date:  2014-10-01       Impact factor: 9.079

8.  Absolute lymphocyte count is not a suitable alternative to CD4 count for determining initiation of antiretroviral therapy in fiji.

Authors:  Dashika A Balak; Karen Bissell; Christine Roseveare; Sharan Ram; Rachel R Devi; Stephen M Graham
Journal:  J Trop Med       Date:  2014-10-27

9.  Results from implementing updated 2012 World Health Organization Guidance on early-warning indicators of HIV drug resistance in Zimbabwe.

Authors:  More Mungati; Mutsa Mhangara; Janet Dzangare; Owen Mugurungi; Tsitsi Apollo; Elizabeth Gonese; Peter H Kilmarx; Christine C Chakanyuka-Musanhu; Gerald Shambira; Mufuta Tshimanga
Journal:  J Epidemiol Res       Date:  2016

Review 10.  Integrated care as a means to improve primary care delivery for adults and adolescents in the developing world: a critical analysis of Integrated Management of Adolescent and Adult Illness (IMAI).

Authors:  Ashwin Vasan; Andrew Ellner; Stephen D Lawn; Sandy Gove; Manzi Anatole; Neil Gupta; Peter Drobac; Tom Nicholson; Kwonjune Seung; David C Mabey; Paul E Farmer
Journal:  BMC Med       Date:  2014-01-14       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.